1002360-09-9

Basic information

• Product Name: (S)-1-Boc-3-(Cbz-amino)-piperidine
• Synonyms: (S)-1-Boc-3-(Cbz-amino)-piperidine ;(S)-1-N-BOC-3-N-(CBZ-AMINO)PIPERIDINE;(S)-3-BENZYLOXYCARBONYLAMINO-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(3S)-3-[[(Phenylmethoxy)carbonyl]amino]-1-piperidinecarboxylic acid tert-butyl ester;(S)-tert-Butyl 3-(((benzyloxy)carbonyl)aMino)piperidine-1-carboxylate;tert-butyl (3S)-3-(benzyloxycarbonylamino)piperidine-1-carboxylate;-tert-Butyl 3-(((benzyloxy)
• CAS NO: 1002360-09-9
• Molecular Formula: C18H26N2O4
• Molecular Weight: 334.41004
• Mol File: 1002360-09-9.mol

Chemical Properties

• Boiling Point: 471.6 °C at 760 mmHg
• Flash Point: 239 °C
• Appearance: /
• Density: 1.15
• Storage Temp.: 2-8°C
• PKA: 12.05±0.20(Predicted)
• CAS DataBase Reference: (S)-1-Boc-3-(Cbz-amino)-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-Boc-3-(Cbz-amino)-piperidine(1002360-09-9)
• EPA Substance Registry System: (S)-1-Boc-3-(Cbz-amino)-piperidine(1002360-09-9)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 1002360-09-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-1-Boc-3-(Cbz-amino)-piperidine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to react readily with other compounds. Its presence in the synthesis process aids in the creation of new drugs with potential therapeutic applications.
Used in Organic Chemistry Research:
In the field of organic chemistry, (S)-1-Boc-3-(Cbz-amino)-piperidine serves as a valuable subject for studying chemical reactions and mechanisms. Its unique structure and reactivity contribute to a deeper understanding of organic processes and the development of innovative synthetic methods.
Used in the Development of Synthetic Routes:
(S)-1-Boc-3-(Cbz-amino)-piperidine is utilized as a building block in the development of new synthetic routes for the preparation of biologically active compounds. Its versatility in organic synthesis allows for the exploration of novel pathways to produce complex molecules with potential medicinal properties.
Used in the Preparation of Biologically Active Compounds:
As a component in the synthesis of biologically active compounds, (S)-1-Boc-3-(Cbz-amino)-piperidine plays a crucial role in the advancement of drug discovery. Its incorporation into the molecular structures of these compounds can lead to the development of new therapeutic agents with improved efficacy and selectivity.

Upstream product

• 4129-17-3 diphenylphosphoranyl azide 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 501-53-1 benzyl chloroformate 
• 144243-24-3 tert‐butyl 3‐aminopiperidine‐1‐carboxylate 
• 188111-79-7 tert-butyl (3R)3-aminopiperidine-1-carboxylate 
• 625471-18-3 tert-butyl (3S)-3-aminopiperidine-1-carboxylate 

Downstream Products

• 129888-62-6 N-(1-tert-butoxycarbonyl-3-piperidyl)acetamide 

Relevant articles and documents

Discovery of a novel bicyclic compound, DS54360155, as an orally potent analgesic without mu-opioid receptor agonist activity

We synthesized derivatives of a natural alkaloid, conolidine, and evaluated these derivatives in the acetic acid-induced writhing test and formalin test in ddY mice after oral administration. As a result, we identified (5S)-6-methyl-1,3,4,5,6,8-hexahydro-7H-2,5-methano[1,5]diazonino[7,8-b]indol-7-one sulfate salt, 15a (DS54360155), with a unique and original bicyclic skeleton, as an analgesic more potent than conolidine. Moreover, 15a did not exhibit mu-opioid receptor agonist activity.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in?vivo anti-tumor activity

Novel 1H-benzo[d]immidazole-4-carboxamide derivatives bearing five-membered or six-membered N-heterocyclic moieties at the 2-position were designed and synthesized as PARP-1 inhibitors. Structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values in the single or double digit nanomolar level. Some potent PARP-1 inhibitors also had similar inhibitory activities against PARP-2. Among all the synthesized compounds, compound 10a and 11e displayed strong potentiation effects on temozolomide (TMZ) in MX-1?cells (PF50?=?7.10, PF50?=?4.17). In?vivo tumor growth inhibition was investigated using compound 10a in combination with TMZ, and it was demonstrated that compound 10a could strongly potentiate the cytotoxicity of TMZ in MX-1 xenograft tumor model. Two co-crystal structures of compounds 11b and 15e complexed with PARP-1 were achieved and demonstrated a unique binding mode of these benzo-imidazole derivatives.

AMIDE DERIVATIVE

The present invention relates to a compound of the formula (I) being useful as a renin inhibitor, or a pharmaceutically acceptable salt thereof. wherein R1a is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; R1b is an optionally substituted C1-6 alkoxy, etc.; R1c is a hydrogen atom, an optionally substituted C1-6 alkoxy, etc.; R2 is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and each is a group of the formula: -A-B (in which A is a single bond, -(CH2)sO-, - (CH2)sN(R4)CO-, etc., B is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.), etc.; R4 is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; s is 0, etc.; and n is 1, etc.

Indazole-carboxamide compounds

The invention provides novel indazole-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.

3-substituted piperidines comprising urea functionality, and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds comprising urea functionality. A second aspect of the present invention relates to the use of the novel heterocyclic compounds comprising urea functionality as ligands for various cellular receptors, including opioid receptors, other G-protein-coupled receptors and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds comprising urea functionality as analgesics.